Two studies demonstrated that deletion of the von Hippel-Lindau tumour suppressor gene (VHL), a negative regulator of HIF, to promote HIF activity improves the anti-tumour immunity of CD8+ T cells against primary and metastatic melanoma, and colorectal cancer in murine models. The gene discussed is CD8A; the disease is neoplasm.